Oncology stakeholders must be prepared to adapt to change as cancer incidence and spending continue to rise, new diagnostics and treatments are adopted, and the long-term impacts of the COVID-19 pandemic become clearer. We’ve identified three key drivers that are reshaping the cancer care landscape.

Download the report with strategic insights on the drivers below:

The favorable adoption outlook for several recent innovations is altering the boundaries of cancer care timelines, pulling forward diagnosis and treatment and extending survivorship.

Multiple stakeholders are pursuing a wide variety of tactics — from adoption of biosimilars to outcomes-based contracting — to reduce cancer drug costs as spending continues to rise.

Preliminary evidence suggests advanced stage diagnoses have increased post-peak pandemic, but more data is needed before we can understand the long-term impact of missed screenings because of COVID-19.